Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | LPL | P06858 | 11/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17660374 | 0.85 | JAK2 (0.41) | JAK2BTKLPLLIPGUCHL1 | |
| SCHEMBL15000450 | 0.83 | PDCD1 (0.42) | JAK2BTKLPLLIPGUCHL1 | |
| SCHEMBL29712932 | 0.83 | PDCD1 (0.42) | JAK2BTKLPLLIPGUCHL1 | |
| SCHEMBL29288003 | 0.83 | JAK2 (0.38) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL11927624 | 0.82 | LPL (0.44) | JAK2BTKLPLLIPG | |
| SCHEMBL23210795 | 0.80 | JAK2 (0.36) | JAK2BTKLPLLIPG | |
| SCHEMBL14527533 | 0.80 | LIPG (0.47) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL31436730 | 0.80 | JAK2 (0.36) | JAK2BTKLPLLIPG | |
| SCHEMBL21928151 | 0.78 | JAK2 (0.37) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL2988520 | 0.78 | LIPG (0.40) | JAK2BTKLPLLIPGCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | JAK2 430/4885BTK 1749/4885LPL 1738/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | JAK2 2617/4885BTK 2376/4885LPL 2247/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | JAK2 430/4885BTK 1749/4885LPL 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.